Biotechnology

Vaxart

Vaxart released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 39.23 M (forecast USD 65.5 M), actual EPS USD 0.0199 (forecast USD 0.02)

Vaxart to Release FY2026 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 65.5 M, EPS USD 0.02

Vaxart released FY2025 Q4 earnings on March 13 During-Market EST, actual revenue USD 104.24 M (forecast USD 35.95 M), actual EPS USD 0.2322 (forecast USD -0.065)

Vaxart released FY2025 earnings on March 13 During-Market EST, actual revenue USD 237.26 M (forecast USD 202.7 M), actual EPS USD 0.0699 (forecast USD -0.21)

Vaxart to Release FY2025 Earnings on March 12 During-Market EST, Forecast Revenue USD 202.7 M, EPS USD -0.21

Vaxart Inc. Director Elaine J. Heron Acquires Common Stock

Vaxart released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 72.41 M (forecast USD 40.1 M), actual EPS USD -0.0355 (forecast USD -0.0666)

Vaxart released FY2025 9 Months earnings on November 13 After-Market (EST), actual revenue USD 133.02 M, actual EPS USD -0.174

Vaxart to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast Revenue USD 40.1 M, EPS USD -0.0666

Vaxart released FY2025 Q2 earnings on August 13 After-Market EST, actual revenue USD 39.73 M (forecast USD 2.033 M), actual EPS USD -0.0656 (forecast USD -0.0866)

Vaxart released FY2025 Semi-Annual earnings on August 13 After-Market EST, actual revenue USD 60.61 M, actual EPS USD -0.134

Vaxart to release FY2025 Q2 earnings on August 13 After-Market EST, forecast revenue USD 2.033 M, EPS USD -0.0866

Vaxart switches from NASDAQ to OTCQX

Vaxart Inc. Receives NASDAQ Delisting Notice

Vaxart Annual Shareholders Meeting Approves Director Elections

Vaxart's Annual Shareholders Meeting Elects Directors but Rejects Reverse Split

US Stock Market Rises on Inflation Report

Positive clinical data for Vaxart's second-generation vaccine

Vaxart releases top-line data for norovirus trial

B. Riley Maintains Buy Rating on Vaxart

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

VXRT

LABU

IBBQ

Vaxart (VXRT) has urged shareholders to support its board nominees amid a proxy contest, emphasizing the importance of experienced leadership for its oral vaccine platform. The company reported progress in its COVID-19 trial and other vaccine programs, while detailing financial measures to extend its cash runway. Analysts rate VXRT as a Buy with a $4.00 price target, though execution risks remain. Vaxart focuses on developing oral vaccines for infectious diseases, positioning itself against traditional injectable products.

Tip Ranks

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Dynavax Tech

Vaxart Urges Shareholder Support Amid Proxy Contest, Updates Pipeline

DVAX

SBIO

ARKG

Vaxart has filed a preliminary proxy and urged shareholders to support its board as it progresses with a Phase 2b COVID-19 trial. The trial is fully enrolled with 5,400 participants, and results are expected in early 2027. The company reported a strong financial position with $61M cash, ensuring funding into Q2 2027. Actions taken to extend runway include restoring BARDA funding and a strategic partnership with Dynavax.

TradingView

iShares Global Healthcare

VanEck Biotech ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

VG Health

Health Care Select Sector SPDR

iShares US Pharma

Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027

Vaxart has submitted an initial proxy statement and communicated with investors regarding recent developments. Additionally, the government plans to allocate $15 million for a new hospital in a rural area, which will have 100 beds and serve 50,000 residents, aiming to enhance healthcare access and quality.

Unusual Whales

Vaxart submits initial proxy statement and sends letter to investors in recent development.

A California federal jury has returned a complete defense verdict for Armistice Capital LLC and its executives, clearing them of all claims in a securities class action brought by Vaxart Inc. investors. The jury deliberated for less than four hours after a two-week trial, where plaintiffs alleged market manipulation and insider trading. Defense argued that the allegations were based on isolated phrases and that the press releases were accurate. The case originated from stock sales by Armistice following Vaxart's announcements in 2020. Vaxart settled separately for $12 million in 2022.

prnewswire

09:06 ETJury Returns Full Defense Verdict for Armistice Capital and Its Executives in Vaxart Securities Class Action

DTIL

Altesa BioSciences has enrolled its first patient in the Phase 2b CARDINAL clinical trial, evaluating vapendavir as a treatment for COPD patients affected by rhinovirus. The trial aims to demonstrate that vapendavir can alleviate respiratory symptoms and improve lung function compared to placebo. With 900 participants in the US and UK, the study will assess symptom improvement and other health outcomes. Vapendavir is an investigational antiviral drug targeting rhinovirus, which is responsible for many COPD exacerbations. The trial reflects a shift towards addressing the underlying causes of respiratory infections.

Precision Biosciences

MBX Biosciences

GlaxoSmithKline plc

GSK plc Sponsored ADR

07:00 ETAltesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations

Vaxart (OTCMKTS:VXRT) is set to announce its Q1 2026 earnings on May 11, with expectations of $0.02 earnings per share and $65.50 million in revenue. The company previously reported $0.24 earnings per share for Q4 2025, exceeding estimates. Vaxart shares recently traded down 1.6% to $0.76, with a market cap of $183.29 million. Analysts have upgraded Vaxart to a "buy" rating, and institutional investors hold 18.05% of the stock. Vaxart focuses on developing oral vaccines using a proprietary platform.

Market Beat

Raymond James Financial

Invesco

Goldman Sachs

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

GS Hldg R

Vaxart (VXRT) Expected to Announce Quarterly Earnings on Monday

Earnings Watch

Vaxart | 10-K: FY2025 Revenue Beats Estimate at USD 237.26 M

Vaxart, Inc. has appointed James B. Breitmeyer, M.D., Ph.D., a veteran biotech executive, to its Board of Directors. This move aims to enhance oversight of Vaxart's clinical programs and support the advancement of its oral vaccine platform, which targets various viruses including coronavirus and HPV. The company is known for its innovative pill-based delivery system for vaccines. Analysts currently rate Vaxart's stock (VXRT) as a Buy with a price target of $4.00, although concerns about sustainability and historical volatility remain.

Bavarian Nordic A/S

Eli Lilly

Vaxart Adds Veteran Biotech Leader to Board

CYTOF

Vax has appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors, effective immediately. He is the current CEO of Altay Therapeutics and has extensive experience in the biotech sector. The Board has determined that he meets independence standards and will receive standard compensation and indemnification. This appointment follows a recommendation by the Nominating and Governance Committee.

Vaxart(VXRT.US)